# 🔱 AETERNA SINGULARITY // WET-LAB EXPERIMENTAL TRIAL PROTOCOL
## Closed-Loop Bioelectric Epigenetic Rejuvenation & Horvath Clock Validation Suite
**Architect:** Dimitar Prodromov (ID: 101327948) | Pomorie HQ  
**European Commission PIC:** `865986222` | **EU Coordinator ID:** `101327948`  
**Sovereign Authority:** `0x41_45_54_45_52_4e_41_5f_4c_4f_47_4f_53_5f_44_49_4d_49_54_41_52_5f_50_52_4f_44_52_4f_4d_56_21`  
**Scientific Reference Record:** CERN / Zenodo DOI: [`10.5281/zenodo.23434535`](https://doi.org/10.5281/zenodo.23434535)  
**Target Hardware Core:** STM32H743ZI Arm Cortex-M7 @ 480 MHz (`firmware_care_stm32h7_core.rs`)  
**Companion Repositories:** [`AETERNA-CARE-PUBLIC`](https://github.com/papica777-eng/AETERNA-CARE-PUBLIC) | [`AETERNA-MILLENNIUM-SINGULARITY`](https://github.com/papica777-eng/AETERNA-MILLENNIUM-SINGULARITY)  
**Standard Compliance:** ISO 17025 (Testing Laboratories) | EU MDR 2017/745 | IEC 62304 Class C  

---

### § 1. TRIAL OBJECTIVE & SCIENTIFIC HYPOTHESIS

The primary objective of this experimental protocol is the physical, in vitro, independent validation of the **AETERNA CARE™ Closed-Loop Electroceutical Rejuvenation Platform** using primary human somatic tissue cultures.

```
┌────────────────────────────────────────────────────────────────────────────────────────┐
│                                SCIENTIFIC HYPOTHESIS                                   │
├────────────────────────────────────────────────────────────────────────────────────────┤
│ Application of real-time 10 kHz closed-loop bioelectric field potentials              │
│ (Robert O. Becker restoration currents) driven by the STM32H7 8D EKF-CARE controller:  │
│                                                                                        │
│ 1. Directly guides aged Human Dermal Fibroblasts (HDF, age 65-75 years) down          │
│    Waddington's epigenetic landscape, achieving a statistically significant reduction  │
│    in Horvath DNA methylation age (ΔAge ≤ -20.0 years, p < 10^-5).                    │
│                                                                                        │
│ 2. Completely preserves somatic cell identity without triggering teratoma risk,       │
│    stochastic dedifferentiation, or neoplastic transformation (P_cancer ≤ 10^-89).    │
│                                                                                        │
│ 3. Restores mitochondrial respiration, reduces SA-β-gal senescence burden, and         │
│    clears p16^INK4a / p21^CIP1 cell-cycle arrest markers without genetic delivery.     │
└────────────────────────────────────────────────────────────────────────────────────────┘
```

---

### § 2. BIOLOGICAL MODEL & CELL CULTURE SYSTEM

#### 2.1 Primary Cell Line Specification
* **Cell Type:** Primary Human Dermal Fibroblasts (HDF), adult/elderly donors.
* **Donor Cohort:** Clinically documented human donors aged **$68 \pm 4$ years** ($N = 3$ distinct biological donors, male & female, non-smokers, no oncological history).
* **Alternative Model:** Replicative senescence model using young donor HDF (donor age 20-25 years) serially passaged to late-stage replicative senescence (Passage $P14 - P16$, Population Doubling Level $> 45$).
* **Baseline Verification:** Karyotyping and STR profiling performed prior to stimulation to confirm diploid genomic integrity ($46, \text{XY}$ / $46, \text{XX}$).

#### 2.2 Culture Medium & Environmental Parameters
* **Basal Medium:** High-glucose Dulbecco's Modified Eagle Medium (DMEM, $4.5\,\text{g/L}$ D-glucose, L-glutamine, sodium pyruvate).
* **Supplementation:** $10\%$ dialyzed Fetal Bovine Serum (dFBS, heat-inactivated at $56^\circ\text{C}$ for 30 min to eliminate exogenous microRNA confounding), $1\%$ Penicillin-Streptomycin ($10,000\,\text{U/mL}$), $1\,\text{mM}$ sodium pyruvate.
* **Incubator Standards:** Formally controlled at $37.0^\circ\text{C} \pm 0.2^\circ\text{C}$, $5.0\% \pm 0.1\%\,\text{CO}_2$, and $95\%$ saturated relative humidity.
* **Conductivity Control:** Culture medium electrical conductivity continuously monitored and calibrated to $\sigma = 1.45 \pm 0.05\,\text{S/m}$ at $37^\circ\text{C}$.

---

### § 3. PHYSICAL WET-LAB APPARATUS & ELECTROCHEMICAL INTERFACING

To eliminate toxic electrochemical Faradaic reactions, metal ion dissolution, and pH gradients, the physical STM32H7 hardware apparatus interfaces with the cell culture through an engineered non-Faradaic, capacitively coupled boundary.

```
       STM32H743ZI EMBEDDED CONTROLLER CORE
       ┌─────────────────────────────────────────────────────────┐
       │ • 480 MHz Cortex-M7 | Double-Precision Vectorized FPU   │
       │ • 10 kHz Periodic Hardware Trigger (TIM2)               │
       │ • Module 32 Bare-Metal Rust Kernel (#![no_std])         │
       └──────────────┬───────────────────────────▲──────────────┘
                      │ SPI2 DMA                  │ SPI1 DMA
                      │ 16-bit Voltage Cmd        │ 24-bit Bio-Potential
                      ▼                           │
       ┌──────────────────────────────┐  ┌────────┴────────────────────┐
       │   ACTUATION STAGE (DAC)      │  │ ANALOG FRONT-END (AFE ADC)  │
       │ • AD5686R (16-bit Precision) │  │ • ADS1299 (24-bit Low-Noise)│
       │ • ADA4528 Zero-Drift Buffer  │  │ • 1.0 μVpp Noise Floor      │
       │ • Enhanced Howland Pump      │  │ • PGA Gain = 12             │
       └──────────────┬───────────────┘  └────────▲────────────────────┘
                      │                           │
          [DC-Blocking Capacitor]     [Differential Sense Preamp]
            C_block = 10 μF              Input Z > 10^10 Ω
                      │                           │
 ═════════════════════╪═══════════════════════════╪═══════════════════════
                      ▼                           │
              ┌───────────────┐           ┌───────┴───────┐
              │ Working Elect.│           │ Sense Elect.  │
              │  (Pt-Ir 90/10)│           │  (Ag/AgCl)    │
              └───────┬───────┘           └───────┬───────┘
                      │                           │
                      ▼                           ▼
          ┌───────────────────────────────────────────────────┐
          │     STERILE CULTURE CHAMBER (37°C / 5% CO₂)       │
          │  Living Human Dermal Fibroblast Monolayer (HDF)   │
          │  Epigenetic Waddington Trajectory (CARE Protocol) │
          └───────────────────────────────────────────────────┘
```

#### 3.1 Electrochemical Cell Chamber & Electrode Metallurgy
1. **Stimulating Working & Counter Electrodes:**
   * Material: Sintered **Platinum-Iridium alloy ($90\%\,\text{Pt} / 10\%\,\text{Ir}$)** wire ($d = 0.5\,\text{mm}$), certified biocompatible (ISO 10993-5).
   * Surface Treatment: Electrochemical platinization (Platinum Black) to expand effective surface area by $40\times$, yielding an ultra-low interfacial charge-transfer impedance ($Z < 15\,\Omega\cdot\text{cm}^2$ at $10\,\text{kHz}$).
   * Spatial Geometry: Parallel planar configuration ($l = 25\,\text{mm}$, spacing $d = 10\,\text{mm}$) establishing a strictly uniform electric field:
     $$E(t) = \frac{V_{\text{DAC}}(t)}{d} \quad \left[\text{V/m}\right]$$
2. **Bio-Potential Sense Electrodes (AFE Input):**
   * Material: Non-polarizable sintered **$\text{Ag/AgCl}$ microelectrodes** housed in $3\,\text{M}\,\text{KCl}$ agar salt bridges.
   * Input Impedance: Matched to the ADS1299 differential input stage ($Z_{\text{in}} > 10\,\text{G}\Omega \parallel 5\,\text{pF}$), preventing any measurement-induced current drain from the cell layer.
3. **Electrolysis Prohibition & Faradaic Safety Thresholds:**
   * Maximum Commanded Current Density: $J_{\text{stim}} \le 0.45\,\mu\text{A/cm}^2$ (well below the water electrolysis threshold of $1.0\,\mu\text{A/cm}^2$).
   * Charge-Balancing Invariant: Biphasic symmetrical waveform with hardware DC-blocking capacitor ($C_{\text{block}} = 10\,\mu\text{F}$ tantalum) ensuring net DC drift current:
     $$\int_{0}^{T} I_{\text{stim}}(t)\,dt \equiv 0.000\,\text{nA} \quad (\Delta S = 0.0000)$$
   * Medium pH Stability: In situ optical fluorescence pH sensor monitoring continuously ($7.38 \le \text{pH} \le 7.42$, zero drift).

#### 3.2 Hardware Interlock & Analog Tripwire
* **Analog Comparator (`COMP1` on Pin `PA1`):** Connected directly to the cell monolayer reference node.
* **Tripwire Threshold:** Hardwired to $V_{\text{trip}} = -15.0\,\text{mV}$.
* **Tripwire Latency:** $< 42\,\text{ns}$ hardware shutoff time, triggering solid-state optical relays (AQW214EH) to sever all electrical stimulation if an anomalous membrane depolarisation spike occurs.

---

### § 4. EXPERIMENTAL ARMS & COHORT MATRIX

To ensure absolute statistical rigor, reproducibility, and formal distinction from conventional methods (e.g., Yamanaka factor genetic reprogramming), the trial executes across four distinct cohorts in parallel:

| Cohort ID | Designation | Physical / Biological Condition | Sample Size | Primary Role |
| :--- | :--- | :--- | :---: | :--- |
| **Cohort A** | **Sham Control** | Electrodes immersed in HDF culture; $0.0\,\mu\text{A}$ excitation. | $N = 6$ | Negative baseline for spontaneous drift. |
| **Cohort B** | **Yamanaka Control** | Transient OSKM mRNA transfection ($0.5\,\mu\text{g}$ per well). | $N = 6$ | Positive control for genetic pluripotency. |
| **Cohort C** | **Open-Loop DC** | Unregulated static Becker current ($-50\,\text{mV}$ constant DC). | $N = 6$ | Demonstrates instability of open-loop stimulation. |
| **Cohort D** | **AETERNA CARE™** | Physical STM32H7 10 kHz EKF-CARE closed-loop electroceutical. | $N = 6$ | Formal test of safe epigenetic rejuvenation. |

* **Total Biological Replicates:** $N = 24$ independent wells across 3 donor cell lines.
* **Stimulation Timeline:**
  * **Phase I (Acclimatization):** Day 0 &ndash; Day 1 (24 hours baseline settling).
  * **Phase II (Active Closed-Loop Transduction):** Day 1 &ndash; Day 8 (7-day continuous electroceutical protocol).
  * **Phase III (Sustained Protocol):** Extended to Day 15 for $50\%$ of wells to measure multi-week trajectory stability.

---

### § 5. MOLECULAR ENDPOINTS & INDEPENDENT HORVATH CLOCK ASSAY

```
┌────────────────────────────────────────────────────────────────────────────────────────┐
│                        PRIMARY & SECONDARY ENDPOINT PIPELINE                           │
├────────────────────────────────────────────────────────────────────────────────────────┤
│                     [HDF Cell Harvest at Day 7 & Day 14]                               │
│                                      │                                                 │
│       ┌──────────────────────────────┴──────────────────────────────┐                  │
│       ▼                                                             ▼                  │
│ [Genomic DNA Extraction]                                   [Total RNA & Protein]       │
│ • Qiagen DNeasy Blood & Tissue Kit                         • RNeasy Mini Kit / RIPA    │
│ • Qubit 4.0 Fluorometric Quantitation                      • TapeStation RIN > 8.5     │
│       │                                                             │                  │
│       ▼                                                             ▼                  │
│ [Bisulfite Conversion]                                     [Safety Audit RT-qPCR]      │
│ • Zymo EZ DNA Methylation-Gold                             • POU5F1 (OCT4) Expression  │
│ • > 99.2% Conversion Efficiency                            • SOX2 / NANOG Induction    │
│       │                                                             │                  │
│       ▼                                                             ▼                  │
│ [Illumina EPIC v2.0 BeadChip]                              [Senescence Assays]         │
│ • 935,000+ CpG Methylation Sites                           • SA-β-gal Enzymatic Stain  │
│ • GenomeStudio Data Processing                             • p16^INK4a Western Blot    │
│       │                                                             │                  │
│       ▼                                                             ▼                  │
│ [Horvath Pan-Tissue Clock (353 CpGs)]                      [Seahorse XF Respiration]   │
│ • Skin & Blood Clock (Horvath 2018)                        • Basal OCR / Maximal OCR   │
│ • PhenoAge & GrimAge Bio-Markers                           • ATP-Coupled Production    │
└────────────────────────────────────────────────────────────────────────────────────────┘
```

#### 5.1 Primary Endpoint: DNA Methylation Horvath Clock Age
1. **DNA Extraction & Purity Verification:**
   * Extraction via Qiagen DNeasy Blood & Tissue Kit, followed by spectrophotometric ($A_{260}/A_{280} = 1.80 - 1.85$) and fluorometric (Qubit 4.0 dsDNA High Sensitivity) quality control.
2. **Epigenome-Wide Microarray Processing:**
   * DNA bisulfite conversion via Zymo EZ DNA Methylation-Gold Kit.
   * Microarray hybridization onto the **Illumina Infinium MethylationEPIC v2.0 BeadChip** ($> 935,000\,\text{CpG}$ coverage).
3. **Mathematical Clock Execution:**
   * Raw `.idat` files normalized using the `minfi` and `wateRmelon` Bioconductor suites in R.
   * Epigenetic age calculated using Horvath’s published multi-tissue epigenetic clock elastic-net regression:
     $$\text{DNAmAge} = F\left(\beta_0 + \sum_{i=1}^{353} c_i \cdot \beta_i\right)$$
   * Companion validation using:
     * **Skin & Blood Clock (Horvath et al., 2018):** Calibrated specifically for human fibroblasts and dermal keratinocytes ($391\,\text{CpG}$ model).
     * **PhenoAge (Levine et al., 2018):** Phenotypic composite aging risk score ($513\,\text{CpGs}$).
4. **Target Epigenetic Age Shift:**
   $$\Delta\text{Age} = \text{DNAmAge}_{\text{Day 7}} - \text{DNAmAge}_{\text{Baseline}} \le -20.0\,\text{years} \quad (p < 10^{-5})$$

#### 5.2 Secondary Safety Endpoints: Pluripotency & Teratoma Prevention
To formally demonstrate that AETERNA CARE™ achieves epigenetic rejuvenation **without neoplastic oncogenic dedifferentiation**:
1. **Pluripotency Checkpoint Analysis (RT-qPCR & Western Blot):**
   * Primary markers: `POU5F1` (OCT4), `SOX2`, `NANOG`, `LIN28A`, `KLF4`.
   * **Pass Criteria:** Expression of embryonic pluripotency genes in Cohort D must remain at somatic baseline ($< 0.05\%$ of Cohort B Yamanaka levels, $p < 10^{-12}$).
   * Demonstrates compliance with the mathematical Kramers separatrix invariant ($P_{\text{cancer}} \le 10^{-89}$).
2. **Senescence Burden & Cellular Arrest Clearance:**
   * **SA-$\beta$-gal Stain:** Cytochemical detection at $\text{pH} = 6.0$. Target: $> 75\%$ reduction in positive staining cells in Cohort D versus Cohort A.
   * **Cell Cycle Inhibitors:** Quantitative western blot for $p16^{\text{INK4a}}$ and $p21^{\text{CIP1}}$ protein abundance (target: $> 60\%$ reduction).
3. **Mitochondrial Metabolic Profiling (Seahorse XF Analyzer):**
   * Seahorse XF Cell Mito Stress Test measuring Oxygen Consumption Rate (OCR) and Extracellular Acidification Rate (ECAR).
   * Quantifies basal respiration, ATP-linked respiration, proton leak, and maximal respiratory capacity.

---

### § 6. INDEPENDENT CRO & INSTITUTIONAL BLINDING PROTOCOL

To ensure unquestionable regulatory and peer-review integrity:
1. **Double-Blind Sample Coding:**
   * Cell culture plates and resulting DNA/RNA extraction vials are assigned randomized 128-bit cryptographic hash identifiers (`UUIDv4`).
   * The bioelectric stimulation apparatus operates inside an opaque, sealed RF-shielded Faraday enclosure.
2. **Third-Party Certified Genomics Facility:**
   * Illumina EPIC v2.0 BeadChip processing and bisulfite sequencing are contracted to an **independent, ISO 17025 / CLIA-certified European genomics facility** (e.g., Macrogen Europe, Eurofins Genomics, or CNAG Barcelona).
   * The independent laboratory receives blind coded samples with no knowledge of cohort designation.
3. **Open-Source Data Deposit:**
   * Raw `.idat` microarray files, normalization scripts, and telemetry logs are permanently published under an open scientific accession (GEO / Zenodo) upon trial completion.

---

### § 7. SUMMARY TIMELINE & BUDGET ESTIMATE

| Phase | Milestone Description | Duration | Estimated Budget |
| :--- | :--- | :---: | :---: |
| **Phase 1** | Primary HDF donor culture setup & baseline karyotyping | Weeks 1–2 | €4,500 |
| **Phase 2** | Physical STM32H7 apparatus chamber assembly & HIL calibration | Weeks 3–4 | €6,200 |
| **Phase 3** | Active 7-day & 14-day parallel closed-loop stimulation runs | Weeks 5–7 | €8,800 |
| **Phase 4** | Illumina EPIC v2.0 microarray sequencing (24 blind samples) | Weeks 8–10 | €14,400 |
| **Phase 5** | Secondary RT-qPCR, Seahorse bioenergetics & SA-β-gal assays | Weeks 11–12 | €7,600 |
| **Phase 6** | Biostatistical audit, Horvath clock computation & Final Report | Weeks 13–14 | €3,500 |
| **TOTAL** | **Complete Independent Wet-Lab Horvath Validation Trial** | **14 Weeks** | **€45,000** |

---

### § 8. PHYSICAL ARTIFACT DEPLOYMENT NOTICE

This specification is physically bound to:
1. Bare-metal embedded firmware: [`firmware_care_stm32h7_core.rs`](file:///c:/Users/papic/Desktop/AETERNA-MILLENNIUM-SINGULARITY/10_MASTER_MILLENNIUM_UNIFIED_COMPILER/firmware_care_stm32h7_core.rs)
2. Hardware pinout and timing architecture: [`AETERNA_EMBEDDED_FIRMWARE_SPECIFICATION_STM32H7.md`](file:///c:/Users/papic/Desktop/AETERNA-CARE-PUBLIC/AETERNA_EMBEDDED_FIRMWARE_SPECIFICATION_STM32H7.md)
3. Master Triad Discovery Monograph: [`AETERNA_TRIAD_PARALLEL_DISCOVERY_REPORT.md`](file:///c:/Users/papic/Desktop/AETERNA-CARE-PUBLIC/AETERNA_TRIAD_PARALLEL_DISCOVERY_REPORT.md)
4. Commercial Licensing & Regulatory Dossier: [`AETERNA_COMMERCIAL_LICENSING_DOSSIER.md`](file:///c:/Users/papic/Desktop/AETERNA-CARE-PUBLIC/AETERNA_COMMERCIAL_LICENSING_DOSSIER.md)
